Ticker: MNKD

MannKind Corporation (NASDAQ:MNKD) stock jumped 3.5% on news that the FDA updated Afrezza's prescribing info, simplifying dosing guidance for patients switching from injectable mealtime insulin to inhaled therapy.

MannKind Corporation (NASDAQ: MNKD) is a biopharmaceutical company focused on developing and commercializing innovative therapeutic products, particularly for endocrine and orphan lung diseases. As of the second quarter of 2025, the company reported a mixed financial performance with both positiv...

MannKind Corporation (NASDAQ: MNKD) recently released its financial results for the first quarter ending March 31, 2025. This report highlights significant progress and notable challenges in the company’s operations. Positive Aspects from the Income Statement: Total revenues increased to $78.4 m...